Montaigu-Vendée, near Nantes, France, June 18, 2026 – Clean Cells, a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, today announces the acquisition of Stem Genomics, a provider of next-generation quality controls for stem cell therapy, including the company’s core asset, its iCS-digital PSC technology platform. This strategic purchase complements Clean Cells’ offerings as a GMP specialist for advanced cell therapies, enabling the company to provide clients with proprietary genomic stability testing designed specifically for the testing of human pluripotent stem cells (hPSCs).
Financial terms were not disclosed.
“Cell and gene therapy developers need reliable partners. With this deal, we are expanding our ability to support research teams from their early genomic stability testing through to cell banking and viral safety testing to GMP lot release. Stem Genomics brings its innovative proprietary technology, a strong US footprint and an expert team that understands stem cell biology at a level that takes years to build. This is the missing piece that completes our cell therapy quality control platform,” said Laurent Claisse, CEO of Clean Cells.
« Building Stem Genomics has taken years of dedication. What convinced us to join Clean Cells was simple: the people driving the group and a shared commitment to delivering the best quality genomic services. We built this company to help researchers trust their cell lines and with Clean Cells we can now follow those same clients all the way into the clinic. This is a critical next step for us, » said Nicolas Chapal, CEO of Stem Genomics, the company that he co-founded with Pr. John De Vos and Dr. Saïd Assou, researchers at the University of Montpellier, France.
« This acquisition highlights how we aim to build leaders in specialized life sciences services: with proprietary technology, regulatory expertise and the geographic reach to serve clients wherever they develop. Stem Genomics combined with Clean Cells’ GMP platform and KaryoLogic’s US presence now allows the Clean Biologics Group to cover the full quality control range for the fastest-growing segment of the biopharmaceutical market, » said Ludovic Alonzi, Partner at ARCHIMED, the healthcare-focused private equity firm and Clean Cell’s majority shareholder.
This acquisition by Clean Cells comes at a strategic time. The stem cell assay industry is projected to grow from $4.6 billion in 2025 to $10.27 billion by 2035, at a CAGR of 8.22%. iPSC-derived therapies also represent one of the fastest-growing areas in regenerative medicine, with programs targeting oncology, neurological disorders and rare diseases. At the same time, regulatory bodies around the world are increasingly requiring rigorous genomic integrity documentation before clinical use, driving developers to work with partners who can deliver genomic quality control that is both scientifically robust and scalable.